Drug Profile
Delpazolid - LegoChem Biosciences
Alternative Names: DPZ; LCB-01371; LCB01-0371; RMX 2001Latest Information Update: 08 Mar 2024
Price :
$50
*
At a glance
- Originator LegoChem Biosciences
- Developer HaiHe Biopharma; LegoChem Biosciences
- Class Antibacterials; Oxazolidinones; Small molecules; Triazines
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Bacteraemia; Tuberculosis
- No development reported Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Vancomycin-resistant enterococcal infections
Most Recent Events
- 23 Aug 2023 LegoChem Biosciences plans a phase IIa trial in Nontuberculous mycobacterium infections (Adjunctive therapy) (PO, Tablet) in December 2023 (NCT06004037)
- 28 Aug 2022 No recent reports of development identified for phase-I development in Gram-positive-infections in China (IV)
- 28 Aug 2022 No recent reports of development identified for phase-I development in Methicillin-resistant-Staphylococcus-aureus-infections(In volunteers) in South Korea (IV, Injection)